Get access to our best features

Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE

Summary by Ground News
Six additional weeks of rivaroxaban reduces risk for recurrent venous thromboembolism. In 40 and 43 percent of patients, isolated distal DVT was unprovoked. Proximal DVT or pulmonary embolism occurred in 3 and 4% of patients.
Published 2 months ago · Boone, United States

News Articles

More Filters
All
Left
Center
Right

Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE

WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- For patients with isolated distal deep venous thrombosis (DVT), six additional weeks of rivaroxaban after an initial six-week course of treatment reduces the risk for recurrent venous thromboembolism, according to a study published…

2 months ago
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

No sources with tracked biases.
See less detail